These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34791217)

  • 1. Mouse midbrain dopaminergic neurons survive loss of the PD-associated mitochondrial protein CHCHD2.
    Nguyen MK; McAvoy K; Liao SC; Doric Z; Lo I; Li H; Manfredi G; Nakamura K
    Hum Mol Genet; 2022 May; 31(9):1500-1518. PubMed ID: 34791217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHCHD2 and CHCHD10-related neurodegeneration: molecular pathogenesis and the path to precision therapy.
    Shammas MK; Huang TH; Narendra DP
    Biochem Soc Trans; 2023 Apr; 51(2):797-809. PubMed ID: 37021679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo studies of the ALS-FTLD protein CHCHD10 reveal novel mitochondrial topology and protein interactions.
    Burstein SR; Valsecchi F; Kawamata H; Bourens M; Zeng R; Zuberi A; Milner TA; Cloonan SM; Lutz C; Barrientos A; Manfredi G
    Hum Mol Genet; 2018 Jan; 27(1):160-177. PubMed ID: 29112723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHCHD2 accumulates in distressed mitochondria and facilitates oligomerization of CHCHD10.
    Huang X; Wu BP; Nguyen D; Liu YT; Marani M; Hench J; Bénit P; Kozjak-Pavlovic V; Rustin P; Frank S; Narendra DP
    Hum Mol Genet; 2018 Nov; 27(22):3881-3900. PubMed ID: 30084972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial CHCHD2 and CHCHD10: Roles in Neurological Diseases and Therapeutic Implications.
    Zhou W; Ma D; Tan EK
    Neuroscientist; 2020 Apr; 26(2):170-184. PubMed ID: 31526091
    [No Abstract]   [Full Text] [Related]  

  • 6. CHCHD2 p.Thr61Ile knock-in mice exhibit motor defects and neuropathological features of Parkinson's disease.
    Fan L; Zhang S; Li X; Hu Z; Yang J; Zhang S; Zheng H; Su Y; Luo H; Liu X; Fan Y; Sun H; Zhang Z; Miao J; Song B; Xia Z; Shi C; Mao C; Xu Y
    Brain Pathol; 2023 May; 33(3):e13124. PubMed ID: 36322611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALS and Parkinson's disease genes CHCHD10 and CHCHD2 modify synaptic transcriptomes in human iPSC-derived motor neurons.
    Harjuhaahto S; Rasila TS; Molchanova SM; Woldegebriel R; Kvist J; Konovalova S; Sainio MT; Pennonen J; Torregrosa-Muñumer R; Ibrahim H; Otonkoski T; Taira T; Ylikallio E; Tyynismaa H
    Neurobiol Dis; 2020 Jul; 141():104940. PubMed ID: 32437855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and pharmacologic p32-inhibition rescue CHCHD2-linked Parkinson's disease phenotypes in vivo and in cell models.
    Tio M; Wen R; Choo CN; Tan JB; Chua A; Xiao B; Sundaram JR; Chan CHS; Tan EK
    J Biomed Sci; 2024 Feb; 31(1):24. PubMed ID: 38395904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-linked CHCHD2 mutations impair CHCHD10 and MICOS complex leading to mitochondria dysfunction.
    Zhou W; Ma D; Sun AX; Tran HD; Ma DL; Singh BK; Zhou J; Zhang J; Wang D; Zhao Y; Yen PM; Goh E; Tan EK
    Hum Mol Genet; 2019 Apr; 28(7):1100-1116. PubMed ID: 30496485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of mitochondrial Chchd10 or Chchd2 in zebrafish leads to an ALS-like phenotype and Complex I deficiency independent of the mitochondrial integrated stress response.
    Petel Légaré V; Rampal CJ; Gurberg TJN; Aaltonen MJ; Janer A; Zinman L; Shoubridge EA; Armstrong GAB
    Dev Neurobiol; 2023 Jan; 83(1-2):54-69. PubMed ID: 36799027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in CHCHD2 cause α-synuclein aggregation.
    Ikeda A; Nishioka K; Meng H; Takanashi M; Hasegawa I; Inoshita T; Shiba-Fukushima K; Li Y; Yoshino H; Mori A; Okuzumi A; Yamaguchi A; Nonaka R; Izawa N; Ishikawa KI; Saiki H; Morita M; Hasegawa M; Hasegawa K; Elahi M; Funayama M; Okano H; Akamatsu W; Imai Y; Hattori N
    Hum Mol Genet; 2019 Dec; 28(23):3895-3911. PubMed ID: 31600778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c.
    Meng H; Yamashita C; Shiba-Fukushima K; Inoshita T; Funayama M; Sato S; Hatta T; Natsume T; Umitsu M; Takagi J; Imai Y; Hattori N
    Nat Commun; 2017 Jun; 8():15500. PubMed ID: 28589937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHCHD10 is involved in the development of Parkinson's disease caused by CHCHD2 loss-of-function mutation p.T61I.
    Mao C; Wang H; Luo H; Zhang S; Xu H; Zhang S; Rosenblum J; Wang Z; Zhang Q; Tang M; Shepard MJ; Wang X; Wang Y; Zhuang Z; Shi C; Xu Y
    Neurobiol Aging; 2019 Mar; 75():38-41. PubMed ID: 30530185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
    Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
    Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant Twinkle increases dopaminergic neurodegeneration, mtDNA deletions and modulates Parkin expression.
    Song L; Shan Y; Lloyd KC; Cortopassi GA
    Hum Mol Genet; 2012 Dec; 21(23):5147-58. PubMed ID: 22949510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological characterization of a novel mouse model expressing the PD-linked CHCHD2-T61I mutation.
    Kee TR; Wehinger JL; Gonzalez PE; Nguyen E; McGill Percy KC; Khan SA; Chaput D; Wang X; Liu T; Kang DE; Woo JA
    Hum Mol Genet; 2022 Nov; 31(23):3987-4005. PubMed ID: 35786718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of CHCHD10-CHCHD2 complexes required for respiration underlies the pathogenicity of a CHCHD10 mutation in ALS.
    Straub IR; Janer A; Weraarpachai W; Zinman L; Robertson J; Rogaeva E; Shoubridge EA
    Hum Mol Genet; 2018 Jan; 27(1):178-189. PubMed ID: 29121267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of mitochondrial integrity in midbrain dopaminergic neurons governed by a conserved developmental transcription factor.
    Miozzo F; Valencia-Alarcón EP; Stickley L; Majcin Dorcikova M; Petrelli F; Tas D; Loncle N; Nikonenko I; Bou Dib P; Nagoshi E
    Nat Commun; 2022 Mar; 13(1):1426. PubMed ID: 35301315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
    Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
    J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic analysis of CHCHD2 and CHCHD10 in Italian patients with Parkinson's disease.
    Rubino E; Brusa L; Zhang M; Boschi S; Govone F; Vacca A; Gai A; Pinessi L; Lopiano L; Rogaeva E; Rainero I
    Neurobiol Aging; 2017 May; 53():193.e7-193.e8. PubMed ID: 28108040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.